SAN FRANCISCO, May 15, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentationwill be webcast at the upcoming UBS Global Healthcare Conference on Monday, May 22, 2017 at 1:30 p.m. Eastern time.
The presentation will be accessible via a Webcast through a link
Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Jennifer Ruddock of Nektar Therapeutics415-482-5585
Jodi Sievers of Nektar Therapeutics415-482-5593
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-ubs-global-healthcare-conference-2017-in-new-york-300457593.html
SOURCE Nektar Therapeutics
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All